<DOC>
	<DOCNO>NCT02271516</DOCNO>
	<brief_summary>This study determine maximum tolerance dose ( MTD ) evaluate safety 188Re-BMEDA-liposome patient primary solid tumor advance metastatic stage .</brief_summary>
	<brief_title>evaluate188Re-BMEDA-liposome Patient With Primary Solid Tumor Advanced Metastatic Stage</brief_title>
	<detailed_description>Rhenium-188 ideal radionuclide therapeutic use due maximum beta emission 2.12MeV , short physical half-life 16.9 hour , 155-keV gamma emission imaging purpose . 188Re-BMEDA-liposome consist 2 separate component ( Rhenium-188 liposome ) BMEDA linker . This study aim find MTD , evaluate safety , efficacy profile investigate biodistribution , radioactivity radiation dosimetry 188Re-BMEDA-liposome primary solid tumor metastatic stage patient single intravenous injection course .</detailed_description>
	<criteria>Patient histologically confirm diagnosis primary solid tumor , pathologically radiologically document metastasis Disease measurable evaluable RECIST 1.1 criterion ( Solid Tumors ) Patient metastatic cancer refractory current standard/available therapy brain metastasis serious concurrent infection nonmalignant illness uncontrolled uncontrolled intercurrent illness Immunocompromised significant traumatic injury within 3 week Day 0 History hypersensitivity component study drug</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>